ATE475672T1 - Anti-il-23-antikörper - Google Patents

Anti-il-23-antikörper

Info

Publication number
ATE475672T1
ATE475672T1 AT06802075T AT06802075T ATE475672T1 AT E475672 T1 ATE475672 T1 AT E475672T1 AT 06802075 T AT06802075 T AT 06802075T AT 06802075 T AT06802075 T AT 06802075T AT E475672 T1 ATE475672 T1 AT E475672T1
Authority
AT
Austria
Prior art keywords
antibodies
antigen
binding portions
subunit
treatment
Prior art date
Application number
AT06802075T
Other languages
English (en)
Inventor
Catherine Beidler
Stuart Bright
Craig Dickinson
Kristine Kikly
David Marquis
Alain Vasserot
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE475672T1 publication Critical patent/ATE475672T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06802075T 2005-08-25 2006-08-23 Anti-il-23-antikörper ATE475672T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71133605P 2005-08-25 2005-08-25
US77235506P 2006-02-10 2006-02-10
PCT/US2006/032752 WO2007024846A2 (en) 2005-08-25 2006-08-23 Anit-il-23 antibiodies

Publications (1)

Publication Number Publication Date
ATE475672T1 true ATE475672T1 (de) 2010-08-15

Family

ID=37616511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06802075T ATE475672T1 (de) 2005-08-25 2006-08-23 Anti-il-23-antikörper

Country Status (20)

Country Link
US (1) US7872102B2 (de)
EP (1) EP1937721B1 (de)
JP (1) JP5022367B2 (de)
KR (1) KR101028200B1 (de)
AT (1) ATE475672T1 (de)
AU (1) AU2006283194B9 (de)
BR (1) BRPI0615018A2 (de)
CA (1) CA2619052A1 (de)
CY (1) CY1110792T1 (de)
DE (1) DE602006015830D1 (de)
DK (1) DK1937721T3 (de)
EA (1) EA013506B1 (de)
ES (1) ES2347690T3 (de)
IL (1) IL188312A0 (de)
MX (1) MX2008002179A (de)
NO (1) NO20081465L (de)
PL (1) PL1937721T3 (de)
PT (1) PT1937721E (de)
SI (1) SI1937721T1 (de)
WO (1) WO2007024846A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
LT1931710T (lt) * 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (de) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17- und il-23-antagonisten sowie verwendungsverfahren
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR101709488B1 (ko) * 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
SG2014010573A (en) * 2008-11-12 2014-04-28 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
AU2009327411A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Feed supplement for mammalian cell culture and methods of use
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120264917A1 (en) * 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
ES2776980T3 (es) 2009-12-23 2020-08-03 Merck Sharp & Dohme Línea celular 3M
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
SG190006A1 (en) * 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
EP2583979B1 (de) 2011-10-19 2015-12-16 Effimune Verfahren zur Vorbereitung von menschlichem IL-23 gerichtete Antikörper, gegen die p19
NZ700802A (en) * 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
LT2852615T (lt) 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
EP3689369A1 (de) 2013-03-15 2020-08-05 Amgen, Inc Verfahren zur behandlung von psoriasis unter verwendung eines anti-il-23-antikörpers
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3391905A1 (de) 2015-04-14 2018-10-24 Boehringer Ingelheim International GmbH Behandlung von asthma mittels antikörper gegen il-23a
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
US20170298126A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3848390A1 (de) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Verfahren zur behandlung von krankheiten
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
CN112689643A (zh) 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
TW202540171A (zh) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Ｉｌ－２３抗體組合物及使用方法
TW202540172A (zh) * 2024-02-06 2025-10-16 美商派拉岡醫療公司 Ｉｌ－２３結合蛋白組合物及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045480B2 (ja) * 1996-12-20 2000-05-29 大同メタル工業株式会社 ボーリング盤
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
HK1044170B (en) * 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
AU2005215527B2 (en) * 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
JP5285625B2 (ja) * 2007-02-22 2013-09-11 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコ科動物の免疫系を強化するための組成物及び方法

Also Published As

Publication number Publication date
ES2347690T3 (es) 2010-11-03
WO2007024846A2 (en) 2007-03-01
CA2619052A1 (en) 2007-03-01
AU2006283194B2 (en) 2010-10-21
EA013506B1 (ru) 2010-06-30
CY1110792T1 (el) 2015-06-10
US20090240036A1 (en) 2009-09-24
BRPI0615018A2 (pt) 2011-04-26
KR20080031450A (ko) 2008-04-08
HK1119712A1 (en) 2009-03-13
KR101028200B1 (ko) 2011-04-11
DE602006015830D1 (de) 2010-09-09
IL188312A0 (en) 2008-04-13
NO20081465L (no) 2008-05-15
JP2009506041A (ja) 2009-02-12
US7872102B2 (en) 2011-01-18
EP1937721B1 (de) 2010-07-28
PL1937721T3 (pl) 2010-12-31
EP1937721A2 (de) 2008-07-02
WO2007024846A3 (en) 2007-06-07
AU2006283194B9 (en) 2011-02-03
EA200800417A1 (ru) 2008-06-30
AU2006283194B8 (en) 2010-10-28
DK1937721T3 (da) 2010-10-18
MX2008002179A (es) 2008-04-22
AU2006283194A1 (en) 2007-03-01
JP5022367B2 (ja) 2012-09-12
PT1937721E (pt) 2010-09-17
SI1937721T1 (sl) 2010-11-30

Similar Documents

Publication Publication Date Title
DK1937721T3 (da) Anti-IL-23 antistoffer
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
EA200870050A1 (ru) Анти-il-17-антитела
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2009006891A (es) Anticuerpos cd44.
EA201490677A1 (ru) Связывающие антиген cd27l белки
NO20084878L (no) Humanisert C-kit antistoff
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
DK1951759T3 (da) Anti-EGFR-antistoffer
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
TW200740844A (en) Novel MAdCAM antibodies
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
TW200626171A (en) Fixed dosing of HER antibodies
EA200700225A1 (ru) Аналоги тетрапептида
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201390467A1 (ru) Композиции антител и способы применения
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
EA201290977A1 (ru) Гуманизированные антитела к il-25

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1937721

Country of ref document: EP